Gene Mutations Identified in Inherited Bone Marrow Failure Syndromes

Inherited bone marrow failure syndrome (IBMFS) encompasses a group of genetic disorders that compromise the bone marrow’s capacity to generate adequate healthy blood cells. These inherited abnormalities can lead to chronic anemia, thrombocytopenia, or neutropenia, and they predispose affected individuals to a range of hematologic complications.

Patients with IBMFS face a markedly elevated risk of developing myelodysplastic syndromes (MDS), a collection of blood cancers characterized by the production of abnormal, ineffective cells and a failure to produce sufficient normal cells. The progression from IBMFS to MDS underscores the importance of early monitoring and intervention, as the malignant transformation can accelerate disease progression and reduce overall survival.

Ongoing research into the molecular mechanisms linking inherited marrow defects to MDS is critical for improving risk stratification and therapeutic strategies. By identifying early biomarkers and tailoring surveillance protocols, clinicians aim to mitigate the transition to malignancy and enhance outcomes for individuals living with IBMFS.